Arbutus Biopharma Corp (NASDAQ:ABUS) Given Consensus Rating of “Hold” by Analysts

Shares of Arbutus Biopharma Corp (NASDAQ:ABUS) have received a consensus recommendation of “Hold” from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $4.00.

ABUS has been the topic of a number of recent analyst reports. Chardan Capital downgraded shares of Arbutus Biopharma from a “buy” rating to a “neutral” rating in a research note on Friday, October 4th. ValuEngine raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. B. Riley lowered their target price on shares of Arbutus Biopharma from $7.00 to $3.00 and set a “buy” rating on the stock in a research note on Monday, October 7th. Zacks Investment Research downgraded shares of Arbutus Biopharma from a “buy” rating to a “hold” rating in a research note on Monday, August 12th. Finally, Echelon Wealth Partners downgraded shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Friday, October 4th.

Institutional investors and hedge funds have recently made changes to their positions in the stock. DekaBank Deutsche Girozentrale grew its position in Arbutus Biopharma by 65.2% during the second quarter. DekaBank Deutsche Girozentrale now owns 57,000 shares of the biopharmaceutical company’s stock valued at $129,000 after acquiring an additional 22,500 shares during the last quarter. Bank of Montreal Can grew its position in Arbutus Biopharma by 7.1% during the second quarter. Bank of Montreal Can now owns 1,049,006 shares of the biopharmaceutical company’s stock valued at $2,182,000 after acquiring an additional 69,882 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its position in Arbutus Biopharma by 40.4% during the second quarter. Jacobs Levy Equity Management Inc. now owns 30,593 shares of the biopharmaceutical company’s stock valued at $64,000 after acquiring an additional 8,797 shares during the last quarter. Jennison Associates LLC bought a new position in Arbutus Biopharma during the second quarter valued at approximately $1,306,000. Finally, SG Americas Securities LLC grew its position in Arbutus Biopharma by 27.2% during the second quarter. SG Americas Securities LLC now owns 73,098 shares of the biopharmaceutical company’s stock valued at $152,000 after acquiring an additional 15,644 shares during the last quarter. 36.49% of the stock is currently owned by institutional investors and hedge funds.

Shares of Arbutus Biopharma stock traded up $0.08 on Tuesday, reaching $1.02. The stock had a trading volume of 163,847 shares, compared to its average volume of 330,421. Arbutus Biopharma has a 1 year low of $0.83 and a 1 year high of $5.66. The company has a market cap of $52.87 million, a P/E ratio of -1.00 and a beta of 1.69. The company has a current ratio of 11.32, a quick ratio of 11.32 and a debt-to-equity ratio of 0.10. The business’s 50 day moving average is $1.39 and its two-hundred day moving average is $2.08.

Arbutus Biopharma (NASDAQ:ABUS) last announced its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.11). The company had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.88 million. Arbutus Biopharma had a negative net margin of 1,948.40% and a negative return on equity of 125.64%. On average, equities analysts anticipate that Arbutus Biopharma will post -1.27 EPS for the current fiscal year.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies.

See Also: Understanding Specialty Certificates of Deposit

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.